Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
Source: ipsen.com